Soo Aleman

Hepatitis B, C and D is a liver inflammation caused by three different viruses. Common to these is that they can cause scarring in the liver which can lead to cirrhosis of the liver, with increased risk of liver cancer. Liver cancer is the 6th most common cancer in the world, where viral hepatitis is the most common cause globally. In recent decades, liver complications including liver cancer have increased in Sweden. However, today we have poor knowledge of how these risks look in different groups and how patients with increased risk of liver cancer should be followed up in order to optimally detect cancer in time and introduce preventive measures in persons with high risk factors. The purpose of our project is to identify risks for liver cancer, liver complications and mortality in patients with hepatitis B, C and D, with or without treatment. This will be done by follow-up studies of large groups of hepatitis B, C and D infected patients, and by using data from national registers covering all diagnosed persons with viral hepatitis in Sweden. In Sweden there is a unique opportunity to investigate issues that few in the world can investigate thanks to these comprehensive registers. With this project we want to gain knowledge about how patients with viral hepatitis should follow up adequately to detect liver cancer early, be the basis for further development of new treatments for liver cancer and that treatment for viral hepatitis can be taken after sufficient knowledge of effects and risks of liver cancer. . Through analyzes of how high liver cancer risks are in different groups, well-balanced decisions about who should be examined regularly can be done with ultrasound in monitoring programs and preventive measures be put in place.

Hepatitis B, C and D is a liver inflammation caused by three different viruses. Common to these is that they can cause scarring in the liver which can lead to cirrhosis of the liver, with increased risk of liver cancer. Liver cancer is the 6th most common cancer in the world, where viral hepatitis is the most common cause globally. In recent decades, liver complications including liver cancer have increased in Sweden. However, today we have poor knowledge of how these risks look in different groups and how patients with increased risk of liver cancer should be followed up in order to optimally detect cancer in time and introduce preventive measures in persons with high risk factors. The purpose of our project is to identify risks for liver cancer, liver complications and mortality in patients with hepatitis B, C and D, with or without treatment. This will be done by follow-up studies of large groups of hepatitis B, C and D infected patients, and by using data from national registers covering all diagnosed persons with viral hepatitis in Sweden. In Sweden there is a unique opportunity to investigate issues that few in the world can investigate thanks to these comprehensive registers. With this project we want to gain knowledge about how patients with viral hepatitis should follow up adequately to detect liver cancer early, be the basis for further development of new treatments for liver cancer and that treatment for viral hepatitis can be taken after sufficient knowledge of effects and risks of liver cancer. . Through analyzes of how high liver cancer risks are in different groups, well-balanced decisions about who should be examined regularly can be done with ultrasound in monitoring programs and preventive measures be put in place.